Therefore, the authors proposed that the therapy of savolitinib and osimertinib can prolong the survival of patients with advanced EGFR-TKI-resistant NSCLC and low-level acquired MET amplification. The gene discussed is MET; the disease is non-small cell lung carcinoma.